Showing results (2181-2190 of 2,287) with videos related to

Sort By:
Pageof 229
Eclinicalmedicine|August 25, 2020
Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare systemCian P McCarthy, Sean Murphy, Maeve Jones-O'Connor, et al.
Clinical Trials (London, England)|December 19, 2013
Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorderAndrew A Nierenberg, Louisa G Sylvia, Andrew C Leon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.
The British Journal of Ophthalmology|March 17, 2018
Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projectionsRupert R A Bourne, Jost B Jonas, Alain M Bron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 1996
Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial resultsM T Brown, R E Coleman, A H Friedman, et al.
Journal of Affective Disorders|September 8, 2017
Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trialLouisa G Sylvia, Weilynn C Chang, Masoud Kamali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant gliomaH S Friedman, R E McLendon, T Kerby, et al.
Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Journal of Affective Disorders|July 25, 2016
Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE studyNoreen A Reilly-Harrington, Louisa G Sylvia, Dustin J Rabideau, et al.
The Journal of Clinical Psychiatry|August 10, 2007
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis, Michael E Thase, Madhukar H Trivedi, et al.
Pageof 229